Andrew Slee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrew Slee has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Alvaro Sebastian-Yague
MiNK Therapeutics, Lexington, Massachusetts
57 shared publications - Antoine Tanne
Agenus Inc, Lexington, Massachusetts
57 shared publications - Benjamin Morin
Agenus, Lexington, USA
57 shared publications - Bishnu Joshi
Agenus, Lexington, Massachusetts
57 shared publications - Chloe Delepine
Agenus Inc., Lexington, MA, USA
57 shared publications - Claire Galand
Institut National de la Santé et de la Recherche Médicale, UMRS872, Centre de Recherche des Cordeliers, Paris, France
57 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This dataset contains the binding affinity measurements of the botensilimab and the corresponding parental IgG1 anti-CTLA-4 antibody to human Fc gamma receptors as determined by surface plasmon resonance. It also includes calculated activating to inhibitory (A/I) ratios for each antibody.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This dataset contains the binding affinity measurements of the botensilimab and the corresponding parental IgG1 anti-CTLA-4 antibody to human Fc gamma receptors as determined by surface plasmon resonance. It also includes calculated activating to inhibitory (A/I) ratios for each antibody.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This table provides technical information about the multiplex immunofluorescence studies performed using the Akoya Biosciences CODEX platform. This is crucial for the reproducibility and interpretation of the multiplex immunofluorescence results.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This table provides technical information about the multiplex immunofluorescence studies performed using the Akoya Biosciences CODEX platform. This is crucial for the reproducibility and interpretation of the multiplex immunofluorescence results.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S16 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This dataset examines the relationship between FCGR2A and FCGR3A gene expression and clinical response to anti-PD-1 or conventional anti-CTLA-4 therapies in patients with advanced melanoma. Analysis of multiple clinical trial datasets shows that response to these conventional immunotherapies is not associated with FCGR2A or FCGR3A expression levels. This contrasts with botensilimab's efficacy profile, supporting its unique Fc-dependent mechanism of action. The data further support that FCGR2A and FCGR3A expression could be predictive biomarkers of response to botensilimab, distinguishing it from conventional immunotherapies.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S16 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This dataset examines the relationship between FCGR2A and FCGR3A gene expression and clinical response to anti-PD-1 or conventional anti-CTLA-4 therapies in patients with advanced melanoma. Analysis of multiple clinical trial datasets shows that response to these conventional immunotherapies is not associated with FCGR2A or FCGR3A expression levels. This contrasts with botensilimab's efficacy profile, supporting its unique Fc-dependent mechanism of action. The data further support that FCGR2A and FCGR3A expression could be predictive biomarkers of response to botensilimab, distinguishing it from conventional immunotherapies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This dataset summarizes the grade 3 or higher treatment-related adverse events (TRAEs) observed in patients with advanced solid tumors treated in the ongoing phase 1 trial of botensilimab. This safety information is crucial for assessing the risk-benefit profile of botensilimab alone and in combination with balstilimab.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This dataset summarizes the grade 3 or higher treatment-related adverse events (TRAEs) observed in patients with advanced solid tumors treated in the ongoing phase 1 trial of botensilimab. This safety information is crucial for assessing the risk-benefit profile of botensilimab alone and in combination with balstilimab.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This dataset contains the binding affinity measurements of the various mouse anti-CTLA-4 (αCTLA-4) antibodies to mouse Fc gamma receptors as determined by surface plasmon resonance. It also includes calculated activating to inhibitory (A/I) ratios for each antibody. This information is crucial for understanding the Fc-mediated effector functions of the αCTLA-4 antibodies used in the study, providing insight into their in vivo efficacy and mechanisms of action.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This dataset contains the binding affinity measurements of the various mouse anti-CTLA-4 (αCTLA-4) antibodies to mouse Fc gamma receptors as determined by surface plasmon resonance. It also includes calculated activating to inhibitory (A/I) ratios for each antibody. This information is crucial for understanding the Fc-mediated effector functions of the αCTLA-4 antibodies used in the study, providing insight into their in vivo efficacy and mechanisms of action.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This dataset presents comparative results demonstrating the enhanced T cell modulation in the tumor microenvironment promoted by Fc-enhanced anti-CTLA-4 versus the parental anti-CTLA-4 antibody in two specific tumor-bearing mouse models: MC38 and CT26. These data demonstrate the superior ability of Fc-enhanced anti-CTLA-4 to promote T cell infiltration and Treg depletion in the tumor microenvironment. This information is crucial for understanding the mechanistic basis for the improved anti-tumor efficacy of Fc-enhanced anti-CTLA-4 antibodies.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This dataset presents comparative results demonstrating the enhanced T cell modulation in the tumor microenvironment promoted by Fc-enhanced anti-CTLA-4 versus the parental anti-CTLA-4 antibody in two specific tumor-bearing mouse models: MC38 and CT26. These data demonstrate the superior ability of Fc-enhanced anti-CTLA-4 to promote T cell infiltration and Treg depletion in the tumor microenvironment. This information is crucial for understanding the mechanistic basis for the improved anti-tumor efficacy of Fc-enhanced anti-CTLA-4 antibodies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This dataset provides detailed information on the binding characteristics and functional properties of botensilimab. This comprehensive dataset demonstrates botensilimab's high affinity and selectivity for CTLA-4, its ability to effectively block CTLA-4 interactions with its ligands comparable to that of the parental IgG1 anti-CTLA-4 antibody. Importantly, this data further supports that the superior functional attributes of botensilimab are due to the Fc-engineered region and not the variable region of the antibody.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This dataset provides detailed information on the binding characteristics and functional properties of botensilimab. This comprehensive dataset demonstrates botensilimab's high affinity and selectivity for CTLA-4, its ability to effectively block CTLA-4 interactions with its ligands comparable to that of the parental IgG1 anti-CTLA-4 antibody. Importantly, this data further supports that the superior functional attributes of botensilimab are due to the Fc-engineered region and not the variable region of the antibody.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This dataset provides an overview of the baseline demographic characteristics of patients with advanced solid tumors who participated in the ongoing phase 1 trial of botensilimab. This demographic information is crucial for understanding the patient population studied and is valuable for interpreting the safety and efficacy outcomes of the study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This dataset provides an overview of the baseline demographic characteristics of patients with advanced solid tumors who participated in the ongoing phase 1 trial of botensilimab. This demographic information is crucial for understanding the patient population studied and is valuable for interpreting the safety and efficacy outcomes of the study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This dataset summarizes the best overall response of each patient reported in the manuscript. It offers insights into clinical responses to botensilimab alone and in combination with balstilimab across various advanced solid tumor types. Importantly, it includes data on patients who progressed on prior conventional immune checkpoint therapy or have tumor types historically non-responsive to immunotherapy. By providing a patient-level view of treatment efficacy, this dataset allows for a nuanced understanding of how different tumor types and individual patients respond to botensilimab.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This dataset summarizes the best overall response of each patient reported in the manuscript. It offers insights into clinical responses to botensilimab alone and in combination with balstilimab across various advanced solid tumor types. Importantly, it includes data on patients who progressed on prior conventional immune checkpoint therapy or have tumor types historically non-responsive to immunotherapy. By providing a patient-level view of treatment efficacy, this dataset allows for a nuanced understanding of how different tumor types and individual patients respond to botensilimab.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This table presents a comparison of the binding epitopes of botensilimab, ipilimumab, and tremelimumab on human CTLA-4. It highlights the specific amino acid residues on CTLA-4 that are involved in the binding interface for each antibody. This comparison provides insight into binding characteristics of botensilimab relative to established anti-CTLA-4 therapies.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
This table presents a comparison of the binding epitopes of botensilimab, ipilimumab, and tremelimumab on human CTLA-4. It highlights the specific amino acid residues on CTLA-4 that are involved in the binding interface for each antibody. This comparison provides insight into binding characteristics of botensilimab relative to established anti-CTLA-4 therapies.